A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Completed · Phase 2 · Has a placebo group
Conditions studied: Sickle Cell Disease
In brief
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
Key facts
- Study ID
- NCT03401112
- Run by
- Cardurion Pharmaceuticals, Inc.
- People needed
- 100
- Starts
- 2018-01-26
- Expected to finish
- 2020-08-28
- Last updated by the study team
- 2025-05-15
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Benioff Children's Hospital Oakland — Oakland, California, United States
- University of Connecticut Health Center — Farmington, Connecticut, United States
- Foundation for Sickle Cell Disease Research — Hollywood, Florida, United States
- University of Illinois — Chicago, Illinois, United States
- Loretto Hospital — Chicago, Illinois, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- Baylor Scott & White Health — Temple, Texas, United States
- Sandwell & West Birmingham Hospital — Birmingham, United Kingdom
- Bristol Haematology and Oncology Centre — Bristol, United Kingdom
- Royal London Hospital — London, United Kingdom
- University College London Hospital — London, United Kingdom
- Guy's Hospital — London, United Kingdom
- Oxford Cancer & Haematology Centre, The Churchill Hospital — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.